New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient

Balzanelli, Mario Giosuè; Distratis, Pietro; Lazzaro, Rita; D’Ettorre, Ernesto; Nico, Andrea; Inchingolo, Francesco; Dipalma, Gianna; Tomassone, Diego; Serlenga, Emilio Maria; D’Alagni, Giancarlo; Ballini, Andrea; Nguyen, Kieu Cao Diem; Isacco, Ciro Gargiulo

doi:10.3390/jpm12010085

Cited by 12 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the WHO recommends that only children aged over 12 years of age should be routinely vaccinated, while the Center for Disease Control and Prevention (CDC) in the United States recommends everyone ages 5 years and older receive a COVID-19 vaccine to help protect against COVID-19 [ 191 , 199 ]. More studies are required to assess the safety of these vaccines in young patients; some are still ongoing and are studying all age groups, including children younger than 5 years old [ 200 , 201 ]. Extreme caution is advised.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines

Malcangi

Inchingolo

et al. 2022

Children

Self Cite

View full text Add to dashboard Cite

Since the beginning in December 2019, the SARS-CoV-2 outbreak appeared to affect mostly the adult population, sparing the vast majority of children who only showed mild symptoms. The purpose of this investigation is to assess the status on the mechanisms that give children and infants this variation in epidemiology compared to the adult population and its impact on therapies and vaccines that are aimed towards them. A literature review, including in vitro studies, reviews, published guidelines and clinical trials was performed. Clinical trials concerned topics that allowed a descriptive synthesis to be produced. Four underlying mechanisms were found that may play a key role in providing COVID-19 protection in babies. No guidelines are available yet for therapy due to insufficient data; support therapy remains the most used. Only two vaccines are approved by the World Health Organization to be used in children from 12 years of age, and there are currently no efficacy or safety data for children below the age of 12 years. The COVID-19 clinical frame infection is milder in children and adolescents. This section of the population can act as vectors and reservoirs and play a key role in the transmission of the infection; therefore, vaccines are paramount. More evidence is required to guide safely the vaccination campaign.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines

Malcangi

Inchingolo

et al. 2022

Children

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, significant antibody levels are maintained for at least 11 months after infection [ 39 , 40 , 41 ]. S-specific anti-SARS-CoV-2 bone marrow plasma cells (BMPC) were detected in bone marrow aspirates obtained approximately 7 and 11 months post-infection [ 42 ]. A correlation was found between the concentration of anti-S IgG BMPC present in bone marrow aspirate and the circulating anti-S IgG titers at 210–240 days after symptom onset in convalescent individuals [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Investigating the Current Status of SARS-CoV-2 Antibodies in Hospital Staff

et al. 2023

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 had reported over 676 million cases by March 2023. The main aim of this study is to investigate whether the levels of anti-S and anti-N antibodies could precisely indicate the degree of protection against SARS-CoV-2 and affect the probability or time of contracting COVID-19. In this study, a serosurveillance study was conducted in healthcare workers (HCWs) at a regional hospital in Taiwan to evaluate their antibody levels based on infection and vaccination status. Of 245 HCWs enrolled, all have been vaccinated prior to infection. Of these, 85 participants were infected by SARS-CoV-2, while 160 participants were not infected at the time of blood sample collection. The level of anti-SARS-CoV-2 S antibody was significantly higher in the infected HCWs than in the non-infected participants (p < 0.001). It is worth noting that the mean duration between the administration of the last dose of the vaccine and the occurrence of SARS-CoV-2 infection was 5.61 ± 2.95 months. Our follow-up survey revealed that the non-infected group had significantly higher levels of antibodies compared to the infected group (all p < 0.001). In conclusion, this study suggests that the level of antibodies could serve as a reflection of the protective efficacy against SARS-CoV-2 infection. It has the implication for vaccine decision-making policies in the future.

show abstract

“…Subsequently, more stable serum antibodies secreted by long-lasting BMPC are detected. In fact, analysis of bone marrow aspirates obtained approximately 7 and 11 months post-infection revealed S-specific anti-SARS-CoV-2 BMPC [ 67 , 68 , 69 , 70 ]. Consequently, circulating anti-S IgG titers at 210–240 days after symptom begin in convalescent individuals is related with the concentration of anti-S IgG BMPC present in the bone marrow aspirate [ 40 , 62 ].…”

Section: Discussionmentioning

confidence: 99%

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

et al. 2022

View full text Add to dashboard Cite

The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood type, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRna Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab controls were performed every 15th of the month continuously. However, the enrolled patients’ activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari “Aldo Moro” led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient.

show abstract

New Translational Trends in Personalized Medicine: Autologous Peripheral Blood Stem Cells and Plasma for COVID-19 Patient

Cited by 12 publications

References 40 publications

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines

Investigating the Current Status of SARS-CoV-2 Antibodies in Hospital Staff

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

Contact Info

Product

Resources

About